Verantos is the global leader in high-validity real-world evidence for life sciences organizations. By incorporating robust clinical narrative data and artificial intelligence, Verantos is the first company to generate high-validity evidence at scale across therapeutic areas with measured accuracy, completeness, and traceability. Credible evidence accelerates clinical development, market access, medical affairs, pharmacovigilance, and regulatory initiatives.
Verantos is therapeutic area-agnostic. Whereas most companies concerned with data accuracy operate in oncology and/or rare disease, where cohort sizes are smaller, Verantos provides data and services across therapeutic areas, with scalability to thousands of patients enabled by AI.
Verantos sources routinely collected healthcare data from the entire patient record, including unstructured EHR narrative, structured EHR (e.g. problem lists), medical and pharmacy claims, and registries. We leverage our Verantos Research Network, which consists of academic medical centers and community health systems in multiple geographies for population diversity and representativeness. The entire patient journey, beginning in primary care, is captured.
Verantos offers both high-quality RWD and high-validity RWE generation. Using high-quality RWD is one of the prerequisites for achieving high validity in RWE. Verantos’ RWD offering, Pragmatic Registry is a prospective registry of study subjects generated from routinely collected, real-world data. It provides a robust view of the patient journey, including clinical and financial parameters. The registry includes industry-standard data elements with configurable variables and endpoints. The product name is consistent with the idea of pragmatic trials, which are based on RWD. Verantos’ RWE offering, Observational Studies, includes study design and analysis to generate high-validity RWE.
